Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOX4 and Cetuximab for Rectal Cancer
NCT00580073Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2007
- Primary completion
- Nov 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in rectal cancer, sponsored by University of Wisconsin–Madison. Started Dec 2007; status: terminated.
02
Drugs
cetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00580073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580073.